Diagnosed with multiple myeloma at age 46, Linda Huguelet has been leading the Chattanooga Multiple Myeloma Networking group along with her husband since February 2011. In 2010, Linda underwent an autologous stem cell transplant and was in remission for almost four years before her first relapse. She repeated induction therapy for Revlimid®/Velcade/Dex and went through complete remission while continuing treatment with Velcade maintenance. In May 2016, her numbers began to climb again; she maintained a VGPR with Empliciti®/Revlimid/Dex for almost 2 years. She is currently responding well to Darzalex®/Pomalyst®/Dex. Linda will be attending the ASH conference with the IMF for the ninth time and is excited to learn about the latest developments in myeloma care. 

Follow Linda on Twitter: @LindaMYELOMA
Support Group Website: Chattanooga Area Multiple Myeloma Networking Group

 

Bispecifics and the Hope They Bring 

Bispecifics and the Hope They Bring 

I’m very encouraged by all the abstracts related to bispecifics because they offer a unique way to attack myeloma. As we all know, myeloma is very smart and sly. It continually changes to evade the current treatment and can become more high-risk over time which complicates things even more. Finding new ways to outsmart myeloma becomes ever important as the number of relapses increases.  Ultimately, you never want to run out of lily pads to jump to and this requires novel methods of...

read more
Symposiums Promise Many New Lily Pads

Symposiums Promise Many New Lily Pads

Today was filled with educational symposiums that offered medical professionals attending the 63rd American Society of Hematology (ASH) conference the opportunity to earn continuing education credits.  For me, it provided a glimpse of what is to come this weekend and it reconfirmed that there are many more treatment lily pads that I can leap to in the future. Thanks to the International Myeloma Foundation (IMF) and our generous sponsors, this is my 9th year attending this conference.  Every...

read more
Pre-ASH Blog: The Number of Lily Pads Continue to Increase

Pre-ASH Blog: The Number of Lily Pads Continue to Increase

When I was first diagnosed with myeloma in the Spring of 2010, one of my biggest concerns was the number of approved treatments and who would be doing research on a cancer that affects relatively few people. I quickly learned that there was a very active research scene for myeloma and one of my doctors told me that like frogs on lily pads, I would leap from one treatment to another as needed.   I’m now on my 4th lily pad and began taking my current treatment regimen...

read more